Advertisement
U.S. markets open in 5 hours 4 minutes

XBiotech Inc. (XBIT)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Visitors trend2W10W9M
6.86+0.03 (+0.44%)
At close: 04:00PM EST
6.86 0.00 (0.00%)
After hours: 04:02PM EST
Full screen
Trade prices are not sourced from all markets
Previous Close6.83
Open6.82
Bid6.73 x 100
Ask7.06 x 100
Day's Range6.82 - 7.20
52 Week Range3.60 - 9.96
Volume43,440
Avg. Volume47,363
Market Cap209.117M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateNov 13, 2024
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateJul 15, 2021
1y Target EstN/A
  • Associated Press Finance

    XBiotech: Q2 Earnings Snapshot

    AUSTIN, Texas (AP) — XBiotech Inc. XBIT) on Monday reported a loss of $13 million in its second quarter. The Austin, Texas-based company said it had a loss of 43 cents per share.

  • GlobeNewswire

    XBiotech Results from Randomized Double-Blinded Phase 1/2 Study Suggest Potential Breakthrough Treatment for Advanced Pancreatic Cancer

    Findings Show Trends for Reduced Toxicities and Better Outcomes for Subjects Receiving ONIVYDE/5-FU Combination and Targeted anti-IL-1alpha TherapyAUSTIN, Texas, June 18, 2024 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today data from its Phase 1/Phase 2 randomized, double-blind, placebo-controlled multi-center study for advanced pancreatic cancer. Known as 1-BETTER, the study examined Natrunix (anti-interleukin-1alpha) antibody in combination with an established chemotherapy regimen